# Annals of Oncology

Source: https://onco.cc/journals/annals-of-oncology/  
OnCo record `annals-of-oncology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Annals of Oncology is ESMO's flagship journal, publishing European phase 3 trials, the ESMO Clinical Practice Guidelines and the abstract books for the ESMO Congress.

## Summary

Annals of Oncology appears monthly and publishes the ESMO Clinical Practice Guidelines (free to read), ESMO-MCBS benefit scores, trial results often presented at ESMO Congress, translational biomarker studies and the ESMO congress abstract supplements. Published by Elsevier since 2019 (previously Oxford University Press). Hybrid access.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Ann Oncol; src-annals-oncology
- Publisher: Elsevier
- Scope: clinical oncology
- Access: hybrid

## Notes

- Holds: ESMO journal: trials, ESMO guidelines, ESMO-MCBS scorecards and congress abstracts. Access: Paywalled; guidelines and abstracts free.

## Sources

- ESMO Guidelines: https://www.esmo.org/guidelines

## Connected records

- collections: [ESMO Clinical Practice Guidelines & MCBS](https://onco.cc/collections/esmo-guidelines/), [ESMO Congress](https://onco.cc/collections/src-esmo-congress/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- key papers: [A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study](https://onco.cc/key-papers/paper-peter-thuss-patience-ann-oncol-2019/), [Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1](https://onco.cc/key-papers/paper-solar-1-ann-oncol-2021-update/), [Anti-PD-1 checkpoint inhibitor therapy in acral melanoma: a multicentre study of 193 Japanese patients](https://onco.cc/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/), [Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042](https://onco.cc/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/), [Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/), [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/), [Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline](https://onco.cc/key-papers/paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021/), [Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/), [Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-peccatori-ann-oncol/), [Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study](https://onco.cc/key-papers/paper-capitello-281-ann-oncol-2026/), [Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial](https://onco.cc/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/), [Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program](https://onco.cc/key-papers/paper-cardoso-ann-oncol/), [Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer](https://onco.cc/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/), [Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival](https://onco.cc/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/), [Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set](https://onco.cc/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/), [Combined androgen blockade in androgen receptor-positive salivary gland carcinoma](https://onco.cc/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/), [Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study](https://onco.cc/key-papers/paper-roar-ann-oncol-2022-update/), [Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study](https://onco.cc/key-papers/paper-nct03742102-ann-oncol-2026/), [Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial](https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/), [Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features](https://onco.cc/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/), [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/), [ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours](https://onco.cc/key-papers/paper-enets-lung-net-consensus-caplin-ann-oncol-2015/), [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://onco.cc/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/), [ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/), [Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†](https://onco.cc/key-papers/paper-bolero-2-ann-oncol-2014-update/), [First-line chemotherapy for malignant peripheral nerve sheath tumour versus other soft tissue sarcomas (EORTC pooled analysis)](https://onco.cc/key-papers/paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011/), [Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study](https://onco.cc/key-papers/paper-keynote-671-ann-oncol-2026-update/), [Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-casali-ann-oncol/), [High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial](https://onco.cc/key-papers/paper-mindact-ann-oncol-2014/), [Improved survival using specialized multidisciplinary board in sarcoma patients](https://onco.cc/key-papers/paper-florence-duffaud-ann-oncol-2017/), [International expert panel consensus on the diagnosis and treatment of inflammatory breast cancer](https://onco.cc/key-papers/paper-dawood-inflammatory-breast-consensus-ann-oncol-2011/), [Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/), [Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial](https://onco.cc/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/), [Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-haanen-ann-oncol/), [Marginal zone lymphomas: ESMO clinical practice guidelines](https://onco.cc/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/), [Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/), [Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial](https://onco.cc/key-papers/paper-gebhart-ann-oncol/), [Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †](https://onco.cc/key-papers/paper-jean-pascal-machiels-ann-oncol-2021/), [Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma](https://onco.cc/key-papers/paper-nct02938299-ann-oncol-2025/), [Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial](https://onco.cc/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/), [Non-epithelial ovarian cancer: ESMO clinical practice guidelines](https://onco.cc/key-papers/paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018/), [NORDIC NEC: predictive and prognostic factors in 305 patients with advanced gastrointestinal neuroendocrine carcinoma](https://onco.cc/key-papers/paper-nordic-nec-sorbye-ann-oncol-2013/), [OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer](https://onco.cc/key-papers/paper-olympiad-ann-oncol-2019-update/), [Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer](https://onco.cc/key-papers/paper-olympia-overall-survival-ann-oncol-2022/), [Overall survival with abemaciclib in early breast cancer](https://onco.cc/key-papers/paper-monarche-ann-oncol-2026-update/), [Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial](https://onco.cc/key-papers/paper-nct02486718-ann-oncol-2023-update/), [Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/), [Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma](https://onco.cc/key-papers/paper-tetzlaff-ann-oncol/), [Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study](https://onco.cc/key-papers/paper-keynote-158-ann-oncol-2022-update/), [Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial](https://onco.cc/key-papers/paper-nct04379635-ann-oncol-2026-update/), [Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I](https://onco.cc/key-papers/paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021/), [Prevalence and mutational determinants of high tumor mutation burden in breast cancer](https://onco.cc/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/), [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-impassion131-ann-oncol-2021/), [Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials](https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/), [Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy](https://onco.cc/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/), [Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-rectal-cancer-guideline-ann-oncol-2017/), [Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer](https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/), [Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma](https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/), [Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study](https://onco.cc/key-papers/paper-nct03778229-ann-oncol-2025/), [Screening older cancer patients: first evaluation of the G-8 geriatric screening tool](https://onco.cc/key-papers/paper-bellera-ann-oncol/), [Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-robin-jones-ann-oncol-2018/), [Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline](https://onco.cc/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/), [Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-jean-pascal-machiels-ann-oncol-2020/), [Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial](https://onco.cc/key-papers/paper-nct05722015-ann-oncol-2025/), [Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto](https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/), [Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial](https://onco.cc/key-papers/paper-olympia-6-year-update-ann-oncol-2026/), [Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer](https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/), [Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015/), [Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02](https://onco.cc/key-papers/paper-her2climb-02-ann-oncol-2026/), [Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion](https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/), [Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023](https://onco.cc/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/), [Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis](https://onco.cc/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/), [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](https://onco.cc/key-papers/paper-alex-ann-oncol-2020-update/), [Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline](https://onco.cc/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/)
- people: [Alan P. Venook](https://onco.cc/people/alan-venook/), [Charles E. Geyer Jr.](https://onco.cc/people/charles-geyer/), [Eric A. Klein](https://onco.cc/people/eric-klein/), [Eric J. Small](https://onco.cc/people/eric-small/), [Eric Van Cutsem](https://onco.cc/people/eric-van-cutsem/), [Florian Lordick](https://onco.cc/people/florian-lordick/), [Marc Ychou](https://onco.cc/people/marc-ychou/), [Martin Jan Schalij](https://onco.cc/people/martin-jan-schalij/), [Renaud de Crevoisier](https://onco.cc/people/renaud-de-crevoisier/), [Stanislaw Klek](https://onco.cc/people/stanislaw-klek/), [Yasumasa Niwa](https://onco.cc/people/yasumasa-niwa/)

---
JSON: https://onco.cc/api/v1/entities/annals-of-oncology.json